Three doses of one-tenth of that of adults creates strong protection against the coronavirus in children under the age of five, the pharmaceutical company Pfizer announced on Monday.
The announcement effectively prepares the ground for regulatory approval by U.S. authorities to vaccinate the youngest age group (ages six months to 4) and thus effectively make the entire population eligible for vaccines.
Such approval by the US authorities would allow many parents more flexibility in isolating their children and would also greatly facilitate educational institutions. Which is expected at these ages.
According to Pfizer data three low-dose vaccines provide protection with 80% efficacy in terms of symptomatic infection in these age groups (i.e., the vaccine protects against severe consequences in case of symptom development in case of infection), but noted that the sample pool they took is too small to Determine that this is indeed the efficiency.
The modern pharmaceutical company has already applied for its vaccine approval for this age group, which is based on only two doses because they are in a higher dose (but not like those of adults).
Now Pfizer is also joining and the U.S. Food and Drug Administration (FDA) is expected to discuss the applications soon.
One of the vaccines may be approved for use this summer, and possibly both.
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us